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Summary
Quinone-based compounds have been exploited to
treat infectious diseases and cancer, with such
chemicals often functioning as inhibitors of key met-
abolic pathways or as prodrugs. Here, we screened
an aziridinyl 1,4-benzoquinone (ABQ) library against
the causative agents of trypanosomiasis, and cutane-
ous leishmaniasis, identifying several potent struc-
tures that exhibited EC50 values of <100 nM.
However, these compounds also displayed signifi-
cant toxicity towards mammalian cells indicating that
they are not suitable therapies for systemic infec-
tions. Using anti-T. brucei ABQs as chemical probes,
we demonstrated that these exhibit different trypano-
cidal modes of action. Many functioned as type I
nitroreductase (TbNTR) or cytochrome P450 reduc-
tase (TbCPR) dependent prodrugs that, following
activation, generate metabolites which promote DNA
damage, specifically interstrand crosslinks (ICLs).
Trypanosomes lacking TbSNM1, a nuclease that spe-
cifically repairs ICLs, are hypersensitive to most ABQ
prodrugs, a phenotype exacerbated in cells also
engineered to express elevated levels of TbNTR or
TbCPR. In contrast, ABQs that contain substituent
groups on the biologically active aziridine do not
function as TbNTR or TbCPR-activated prodrugs and
do not promote DNA damage. By unravelling how
ABQs mediate their activities, features that facilitate
the desired anti-parasitic growth inhibitory effects
could be incorporated into new, safer compounds
targeting these neglected tropical diseases.
Introduction
The protozoan parasites Trypanosoma brucei, T. cruzi
and various Leishmania species are the etiological
agents of human African trypanosomiasis (HAT), Cha-
gas disease and Leishmaniasis, respectively. Spread by
the hematophagous habits of insect vectors, these
pathogens cause more than 55,000 deaths per year and
are prevalent in many regions of the world least able to
deal with the associated economic burden (http://www.
dndi.org/diseases-projects/). Implementation of new sur-
veillance and treatment programmes in conjunction with
improved housing and vector control strategies has
resulted in a dramatic reduction in disease prevalence.
For example, the number of new cases of HAT has
fallen from an estimated peak of 450,000 in 1997 to
below 20,000 in 2014 while Chagas disease has been
eliminated from Chile, Uruguay and several regions of
Argentina and Brazil (Barrett, 2006; Schofield et al.,
2006; WHO, 2014). The success of such strategies has
led to the World Health Organization (WHO) aiming to
eliminate HAT as a public health problem by 2020
(WHO, 2013).
Currently, drugs represent the only viable option to
combat trypanosomal and leishmanial infections
although their use is problematic. They often require
supervision for administration, can be costly, have lim-
ited efficacy and may cause significant toxicity. Addition-
ally, drug resistance is beginning to further limit the
efficacy of the available chemotherapeutic arsenal, with
antimonials no longer recommended as a first line treat-
ment for leishmaniasis on the Indian sub-continent
(Wilkinson and Kelly, 2009; Barrett and Croft, 2012;
Alsford et al., 2013; Perry et al., 2015). In the case of
HAT and Chagas disease, the front line treatments
involve nitroheterocyclic-based prodrugs with nifurtimox
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or benznidazole monotherapies used to target T. cruzi
while nifurtimox, in combination with difluoromethylorni-
thine (DFMO), is used against a form of HAT prevalent
throughout West and Central Africa (Priotto et al., 2009;
Yun et al., 2010; Wilkinson et al., 2011). To mediate
their trypanocidal effects, nifurtimox and benznidazole
undergo an activation reaction catalysed by an FMN-
containing, mitochondrial type I nitroreductase (NTR),
generating cytotoxic reduction products (Wilkinson et al.,
2008; Hall et al., 2011; Hall and Wilkinson, 2012). For
nifurtimox, this results in the production of an unsatu-
rated open chain nitrile while benznidazole is processed
to glyoxal via a series of highly reactive intermediates. As
type I NTRs are expressed by some unicellular eukar-
yotes (including trypanosomes and Leishmania) but not
by metazoan organisms, the bioreductive activity of this
enzyme has been exploited to develop a series of novel
antiparasitic nitroaromatic- and benzoquinone-based pro-
drugs (Wilkinson et al., 2011; Patterson and Wyllie,
2014). Several of these display significant potency against
T. brucei in vitro while exhibiting little or no toxicity
towards cultured mammalian cells.
Quinones represent a class of organic compounds
that contain two carbonyl groups attached to a six mem-
bered carbocyclic backbone. They are ubiquitous in
nature, functioning in various oxidoreductase cascades,
with some natural and synthetic variants being of phar-
macological interest. In the latter case, many quinone-
based agents often function as prodrugs and must
undergo activation before they can mediate their cyto-
toxic effects, reactions catalysed by quinone oxidoreduc-
tases (McKeown et al., 2007; Siegel et al., 2012). Based
on oxygen-sensitivity, such enzymes can be divided into
two groups. Oxygen-sensitive quinone oxidoreductases,
such as NADH cytochrome b5 reductase and cyto-
chrome P450 reductase (CPR), can mediate the
1e– reduction of one of the quinone’s carbonyl oxygens
to form an unstable semiquinone radical that, under
hypoxic conditions, can be further reduced to the hydro-
quinone derivative (Powis, 1989; O’Brien, 1991). How-
ever, in the presence of oxygen, the semiquinone
radical can undergo futile cycling, generating superoxide
anions and regeneration of the parent compound. In
contrast, oxygen-insensitive quinone oxidoreductases,
such as NAD(P)H quinone oxidoreductase 1 (NQO1), cat-
alyse the simultaneous 1e– reduction of both the qui-
none’s carbonyl oxygens to form the hydroquinone
directly (Ernster et al., 1962; Iyanagi and Yamazaki, 1970;
Siegel et al., 2012). Dependent on structural context, this
conversion can result in stable pharmacologically active
products, as is the case for the benzoquinone ansamycin
antibiotics, or unstable metabolites that undergo further
rearrangement before exerting their toxic effects, as seen
with the antitumor agents mitomycin A and b-lapachone
(Siegel et al., 2012).
Due to their favorable redox and electrochemical
properties, compounds containing a quinone pharmaco-
phore represent attractive scaffolds for antimicrobial
drug development (Pinto and de Castro, 2009; Beena
and Rawat, 2013). Screening against trypanosomes has
resulted in the identification of various natural and syn-
thetic lead structures postulated to function as prodrugs
promoting oxidative stress within the parasite or through
formation of toxic bioreductive products (Henderson
et al., 1988; Kubata et al., 2002; Hoet et al., 2004; Pinto
and de Castro, 2009; Ramos et al., 2009; Garavaglia
et al., 2010; Hall et al., 2012). Using recombinant
T. brucei that lack TbSNM1, a DNA repair enzyme that
specifically fixes interstrand crosslinks (ICLs) (Sullivan
et al., 2015), while expressing elevated levels of oxygen-
sensitive (TbCPR) or –insensitive (TbNTR) quinone
oxidoreductases, we demonstrate that many aziridinyl
1,4-benzoquinones (ABQs) possess significant potency
towards trypanosomatid parasites, with different struc-
tures undergoing distinct activation mechanisms to gen-
erate metabolites that subsequently promote DNA
damage within the parasite nucleus.
Results
Antiparasitic activity of aziridinyl benzoquinones
Compounds containing an ABQ core display potent anti-
cancer properties particularly against cells where
NADPH quinone oxidoreductase 1 (NQO1) expression
is upregulated (Lin et al., 1972; Lusthof et al., 1989;
Dehn et al., 2004). Recently, the antiparasitic activities
of such compounds towards Plasmodium falciparum
and T. brucei has been investigated with several poten-
tial lead structures identified (Grellier et al., 2010; Hall
et al., 2012). Here, we have expanded on these initial
trypanosomal screens to evaluate the growth inhibitory
properties of a larger ABQ library against T. brucei, T.
cruzi and L. major (Table 1). Out of the 34 compounds
tested, 20, 14 and 16 had no effect on T. brucei, T. cruzi
and L. major growth, respectively, at concentrations of
up to 10 mM. These were not analysed further. For the
remaining compounds, RH1 exhibited potencies,
expressed as the compound concentration that inhibits
cell growth by 50% (EC50), of <100 nM towards blood-
stream form T. brucei, with a further five (DZQ, ABQ3,
ABQ6, TZQ and ABQ22) exhibiting moderate potency
towards this parasite (EC50 values of 100–500 nM).
Against T. cruzi epimastigotes, DZQ, TZQ and RH1
were highly active, yielding EC50 values <10 nM, with
others displaying high (EC50 values between 10 and
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100 nM; MeDZQ, ABQ22 and ABQ24) or moderate
(EC50 values between 100 and 500 nM; ABQ4, ABQ6
and ABQ14) growth inhibitory effects. When tested
against L. major promastigotes, TZQ exhibited an
EC50 of <10 nM, with three other compounds (DZQ,
RH1 and ABQ25) exhibiting high potency and eight
others yielding moderate potency. Of all the ABQs
analysed, RH1 was the most potent agent tested
against all three parasites, yielding EC50 values of
1961, 361 and 6861 nM against T. brucei, T. cruzi
and L. major, respectively.
Cytotoxicity against mammalian cells
To evaluate whether those ABQs that displayed activity
against the three trypanosomatid parasites exhibited
toxicity to mammalian cells, their inhibitory properties
against differentiated THP-1 cells was determined (Table
1). For all structures tested, an in vitro toxicity was
observed (EC50 values <10 mM), with two compounds,
including RH1, being extremely toxic and yielding EC50
values of <100 nM. Comparison of the mammalian tox-
icity and antiparasitic EC50 data allowed a crude mea-
sure of each agent’s selectivity (the Selectivity Index or
SI) toward the pathogen. In many cases, the ABQs dis-
played a higher potency against THP-1 cells relative to
the parasite, resulting in a SI value <1. Of those that
did display preferential activity against the parasite, the
observed selective toxicity of most was equivalent to
that seen with nifurtimox, an agent whose use in
humans is problematic. The toxicity of these compounds
towards cultured mammalian cells precluded any
attempt to establish the potency of these structures
against the intracellular amastigote forms of T. cruzi and
L. major.
As THP-1 cells are an immortal human monocyte line
and ABQs have potent activity against cancerous cells
(Tan et al., 1984; Lee et al., 1986; Moore et al., 1997), a
series of screens using a selected quinone series on
non-cancerous mouse peritoneal macrophages were
performed. For DZQ, RH1, TZQ and ABQ22, substantial
toxicity towards this line was observed with the com-
pounds generating EC50 values of 255, <100, <100 and
120 nM, respectively. This clearly demonstrates that
ABQs are toxic to primary cells, thus supporting our
THP-1 findings. In light of the mammalian toxicity
issues, our focus on ABQs switched from exploring
them as potential treatments for infectious diseases to
Table 1. Potency of aziridinyl benzoquinones.
T. bruceia T. cruzi L. major
THP-1b
Compound EC50 (nM) SI EC50 (nM) SI EC50 (nM) SI EC50 (nM)
Nifurtimox 27006100 >37 26006 400 >38 62806 40 >16 >100000
ABQ7, 9–12, 16–19, 28, 31, 32, 34 >10000 – >10000 >10000 –
DZQ 27261 1 56 1 36 606 1 3 18165
MeDZQ 698657 1 556 2 16 5606 139 2 885623
ABQ3c 400630 – 62006 1160 – 1996 4 – –
ABQ4 11806160 – 1066 25 – 6636 6 – –
RH1 1961 <5 36 1 <33 686 1 <1 <100
ABQ6 283641 2 2056 53 5 6646 2 2 10676159
ABQ8 670630 4 13006 108 2 18706 184 2 29516 770
ABQ13 >10000 – 55506 240 – >10000 – –
ABQ14 >10000 – 4456 30 – 22706 17 – –
ABQ15 >10000 – 33106 200 – >10000 – –
AZQ 82336272 – 60006 283 – >10000 – –
TZQ 17961 <1 36 1 <33 96 1 <11 <100
ABQ22 14861 1 556 2 3 2186 20 1 138625
ABQ23 2300660 <1 21806 670 <1 3486 166 1 <400
ABQ24 14706120 <1 376 1 <11 4736 123 <1 <400
ABQ25 >10000 – – – 806 6 – –
ABQ26 >10000 – 86386 736 – 23606 230 – –
ABQ27 >10000 – 6206 180 – 2106 10 – –
ABQ29 – – 9756 25 – 1756 5 – –
ABQ30 74006190 <1 9806 25 4 1746 10 22 37506320
ABQ33 >10000 – >10000 – 81576 80 – –
Data represent the EC50 values of various ABQs towards bloodstream form T. brucei, T. cruzi epimastigotes, L. major promastigotes and dif-
ferentiated THP-1 cells. All values are means6 standard deviation of four (parasites) or three (mammalian cells) independent experiments.
a. Activity of DZQ, MeDZQ, RH1, TZQ and ABQ’s 6–9, 14, 15, 20, 22 against T. brucei was previously reported (Hall et al., 2012).
b. Differentiated THP-1 EC50 value towards nifurtimox taken from (Voak et al., 2013). The Selectivity Index (SI) of certain compounds (fold dif-
ference in EC50 values of the THP-1 line relative to parasite) is noted.
c. ABQ3 was unstable with its potency diminishing following repeated freeze/thawing.
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using them as tools to dissect trypanosomal pro-drug
activation pathways and the structure-activity relation-
ships among this class of compound.
Different trypanosomal mechanisms activate aziridinyl
benzoquinone prodrugs
The application of genome-scale RNAi screens has
helped elucidate the trypanocidal mechanism of action of
a number of agents and identify how the affected path-
ways may impinge on drug resistance (Alsford et al.,
2012; 2013). As an initial step to understanding how
ABQs mediate their antiparasitic activities, a loss-of-
function screen was conducted on bloodstream form T.
brucei, using RH1 as the selective agent (Fig. 1A). Treat-
ment of the parasite RNAi library with this compound
resulted in reduced T. brucei growth over the first week
followed by the outgrowth of an RH1-resistant population.
Genomic DNA was extracted from the RH1-selected cells
and RNAi targets were amplified, from which a single
1.1 kbp fragment was identified as the major amplicon
(Fig. 1B). Sequence analysis and comparison against the
reference genome database revealed that this RH1-
resistance-associated fragment mapped to a region
encompassing the 50 untranslated region and 50 coding
sequence of the open reading frame (Gene ID:
Tb927.7.7230 on TriTrypDB - http://tritrypdb.org/tritrypdb/)
for the type I nitroreductase, TbNTR (Fig. 1C). This was
not unexpected given that this protein had been previ-
ously associated with the activation of trypanocidal
nitroheterocyclic-based prodrugs, nifurtimox and benzni-
dazole (Wilkinson et al., 2008; Baker et al., 2011; Hall
et al., 2011; Hall and Wilkinson, 2012) and postulated to
function as a NADH dependent quinone oxidoreductase
(Wilkinson et al., 2008; Alsford et al., 2012; Hall et al.,
2012).
To conclusively show that TbNTR is the key activator
of ABQs, we evaluated the susceptibility of a T. brucei
Tbntr heterozygote line to RH1. These recombinant
cells displayed an EC50 approximately 2.5-fold greater
than that observed using wild type parasites (Fig. 2A)
confirming that reduction of TbNTR expression through
loss of one of the alleles encoding for this oxidoreduc-
tase is sufficient to generate resistance to RH1. As
reduction of TbNTR activity leads to RH1 resistance,
gain of function via over expression of the oxidoreduc-
tase should have the converse effect, generating cells
that are more susceptible to the ABQ. To determine if
Fig. 1. Screening for RH1 resistant determinants using a genome-scale T. brucei RNAi library.
A. The bloodstream form T. brucei RNAi library (Alsford et al., 2012) was co-treated with RH1 (30 nM) and tetracycline (1 mg ml21), the latter
to induce RNAi, with the cumulative cell growth of the culture followed. The arrows correspond to culture dilution and addition of fresh RH1
(30 nM) and tetracycline (1 mg ml21). Genomic DNA (as indicated by stars) was extracted from parasites at days 9 and 12. Insert shows
structure of RH1.
B. Amplification of the RNAi target from the RH1 screen using genomic DNA extracted on day 9 of selection and the LIB2f
(TAGCCCCTCGAGGGCCAGT) and LIB2r (GGAATTCGATATCAAGCTTGGC) primers (lane 1) produced a major fragment mapping to the type
I nitroreductase (Tbntr) locus (gene id Tb927.7.7230 on the TriTrypDB; http://tritrypdb.org/tritrypdb/). M indicates a size marker in bp.
C. Genetic map (black boxes represent protein-coding sequences) of the Tbntr locus, indicating the location of the major RNAi target fragment
(grey box) recovered from the library following RH1-selection.
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this was the case, the quinone-sensitivity of a T. brucei
line engineered to express elevated levels of the
enzyme was evaluated. In agreement with previous
findings, parasites over expressing TbNTR were hyper-
sensitive (approximately fourfold) to RH1 as compared
to controls (Fig. 2B).
To determine whether TbNTR plays a role in activat-
ing other ABQs, the susceptibility of TbNTR over
expressing parasites towards a selected group of com-
pounds, was tested (Table 2). Out of the additional
compounds screened, three (DZQ, MeDZQ and TZQ)
showed the same hypersensitivity profile as RH1, with
TbNTR over expressing T. brucei being up to 3.5-fold
more susceptible to the aziridinyl agents than controls.
In contrast, ABQ22–24 and 30 did not follow this pat-
tern, with the TbNTR over expressers exhibiting an
EC50 equivalent to that observed against control cells.
Dependent on backbone configuration, the carbonyl
oxygen atoms in a quinone can undergo 1 or 2e– reduc-
tion, with the former reaction carried out by a range of
ubiquitous flavoproteins, including CPR, while the latter
is catalysed by enzymes, such as NQO1 and type I
NTRs. To determine whether the trypanocidal activity
displayed by selected ABQs can undergo activation via
a 1e– reduction mechanism, the susceptibility of T. bru-
cei lines engineered to express ectopic copies of the
TbCPR2 or 3 (Hall et al., 2011) to RH1, TZQ and
ABQ22–24 was evaluated (Table 2). With RH1, TZQ,
ABQ23 and ABQ24, the TbCPR over expressing lines
exhibited EC50 values similar to those observed using
control cells, indicating that the 1e– reduction pathway
plays no significant role in their activation. When the T.
brucei line expressing elevated levels of TbCPR2 or 3
was tested against ABQ22, the recombinant lines were
hypersensitive to this tetra-aziridinyl agent relative to
controls (Fig. 2C).
Fig. 2. Susceptibility of T. brucei expressing altered levels of
activator to RH1 or ABQ22.
A. Dose response curve of wild type (solid line) and Tbntr
heterozygous (dotted line) T. brucei to RH1. The extrapolated EC50
values (in nM) of wild type (white bar) and Tbntr heterozygous
(grey bar) T. brucei to RH1 are shown.
B. Dose response curve of wild type (solid line) and TbNTR
overexpressing (dotted line) T. brucei to RH1. The EC50 values (in
nM) of wild type (white bar) and TbNTR overexpressing (grey bar)
T. brucei to RH1 are shown.
C. Dose response curve of wild type (solid line) and TbCPR2
overexpressing (dotted line) T. brucei to ABQ22. The extrapolated
EC50 values (in nM) of wild type (white bar) and TbCPR2
overexpressing (grey bar) T. brucei to RH1 are shown.
All data are means for experiments performed in
quadruplicate6 standard deviation. The asterisk indicates
significant differences in susceptibility (P < 0.01) between wild type
and genetically modified cells to RH1, as assessed by Student’s t
test (GraphPad Software).
Table 2. Growth inhibitory effect of ABQs towards T. brucei
expressing elevated levels of potential activators.
EC50 (nM)
Compounda Control Tbntr11 Tbcpr211
DFMO 275006108 3072061330
(1.12)
332506 5123
(1.21)
Nifurtimox 2980630 315615 (0.11*) –
DZQ 318638 9063 (0.28*) –
MeDZQ 740618 11563 (0.16*) –
RH1 1961 361 (0.16*) 206 3 (1.05)
TZQ 225626 6069 (0.27*) 2846 13 (1.26)
ABQ22 138625 14869 (1.07) 206 3 (0.14**)
ABQ23 29356420 33156540 (1.13) 35566 96 (1.21)
ABQ24 14706120 20906160 (1.42) 16986 23 (1.16)
ABQ30 74006190 867061670 (1.12) –
Data represent the EC50 values of parasites expressing wild type
(control), elevated levels of TbNTR (Tbntr11) or TbCPR2
(Tbcpr211). All values are means6 standard deviation of four inde-
pendent experiments. The fold difference in EC50 values of the over
expressing lines relative to control is given in parentheses. Para-
sites over expressing TbCPR3 behaved similarly to those express-
ing elevated levels of TbCPR2.
a. Trypanocidal activity of DZQ MeDZQ, RH1, ABQ6, TZQ and
ABQ22 towards T. brucei cells over expressing Tbntr was previ-
ously reported (Hall et al., 2012).
*The difference in susceptibility of wild type and Tbntr11 lines to
nifurtimox, DZQ, MeDZQ, RH1 and TZQ was statistically significant
(P < 0.01), as assessed by Student’s t test.
**The difference in susceptibility of wild type and Tbcpr11 lines to
ABQ22 was statistically significant (P < 0.01), as assessed by Stu-
dent’s t test.
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Based on the above data, the trypanocidal activity of
ABQs can be divided into compounds such as RH1 and
TZQ that function as TbNTR-dependent (oxygen-insen-
sitive quinone oxidoreductase) prodrugs, structures
including ABQ22 that function as TbCPR-dependent
(oxygen-sensitive quinone oxidoreductase) prodrugs and
agents such as ABQ23 and 24 that are not activated by
either of these two mechanisms: ABQ23 and 24 may
still function as prodrugs undergoing activation by an
alternative mechanism(s) to that explored here.
Trypanosomes selected for resistance toward RH1 have
reduced NTR expression
A further approach to determine how ABQs mediate
their trypanocidal activity involved the selection of T.
brucei lines resistant to RH1. Wild type bloodstream
form parasites were grown in the presence of RH1 over
a 100 day period, starting with a compound concentra-
tion that inhibits T. brucei growth by 10% (5 nM) and
progressively increasing this to twice the EC50 (40 nM)
(Fig. 3A). The cumulative cell density of selected cul-
tures was followed throughout the experiment. Of the
three replica cultures analysed, two stopped growing
when the selective pressure was increased to 20 nM. In
contrast, cells in the third culture remained viable in
40 nM RH1 and parasites in this population were cloned
by limiting dilution (designated as RH1RC). We then
evaluated the growth properties of two RH1RC lines
(RH1RC1 and RH1RC2) (Fig. 3B). In the absence of RH1,
the doubling time of the two clones was comparable to
the parental line (doubling time of  7.5 hours). When
grown in medium containing RH1 (40 nM), the doubling
time of the resistant clones increased 1.5-fold (dou-
bling time of  10.5 hours); by comparison, no growth of
wild type T. brucei was detected after 24 hrs. Next, we
determined the susceptibility of the RH1RC lines towards
RH1 with this showing that both lines were 3.5-fold
less sensitive to the ABQ than wild type (Fig. 3C and
D); wild type, RH1RC1 and RH1RC2 exhibited EC50 val-
ues of 256 6, 836 2 and 926 1 nM against RH1,
Fig. 3. RH1 resistance selection in T. brucei.
A. Selection of RH1 resistant T. brucei was performed by the stepwise increase of the ABQ (black line). The cumulative cell density of three
independent cultures (grey lines) were monitored throughout the selection with only one of these (RH1R) generating an outgrowth in medium
containing >20 nM RH1. Clones from the RH1R culture were then generated following limiting dilution.
B. Cumulative cell density of wild type T. brucei (black lines) and a clone (RH1RC1) derived from RH1R (grey lines) grown in medium lacking
(solid lines) or containing 40 nM RH1 (dashed lines). Data points are averages6 standard deviation from experiments performed in
quadruplicate. A second RH1R derived clone (RH1RC2) analysed in parallel displayed similar growth properties (data not shown).
C. Dose response curves of wild type T. brucei (black solid line), RH1RC1 (black dashed line) and RH1RC2 (grey solid line) to RH1. All data
points are averages from experiments performed in quadruplicate6 standard deviation.
D. Susceptibility of T. brucei to RH1 as judged by the EC50 values (in nM). The asterisk indicates significant differences in susceptibility
(P < 0.001) between wild type and genetically modified cells to RH1, as assessed by Student’s t test (GraphPad Software).
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respectively. This resistance phenotype was not lost fol-
lowing 100 generations in medium lacking RH1. Indeed,
the resistant lines were still 4.5-fold less sensitive to
the ABQ than controls; wild type, RH1RC1 and RH1RC2
exhibited EC50 values of 196 1, 8663 and 91611 nM
against RH1, respectively. When the above susceptibility
studies were extended to TbNTR-activated prodrugs,
cross-resistance towards nifurtimox, benznidazole, meg-
azol, CB1954 and LH17 was observed (Table 3). This
phenotype was specific to this class of compound, as
the RH1 selected cells were equally sensite to the non
TbNTR-activated compounds, including ABQ22 and
other ICL inducing agents, as wild type T. brucei.
Studies aimed at deciphering the RH1 resistance
mechanism demonstrated that although the Tbntr copy
number was similar and Tbntr gene sequences were
identical in the compound selected and wild type lines,
the RH1RC cells had a lower (50%) Tbntr mRNA
expression level (Fig. 4). Intriguingly, when extended to
genes expressed in the same polycistron as Tbntr, all
the tested ORFs exhibited the same trait in relation to
copy number and transcript levels. The observed reduc-
tion in gene expression within the Tbntr-containing poly-
cistron in the RH1 selected cells is specific to this
region as additional ORFs present elsewhere in the T.
brucei genome (for example Tb927.7.7490 and
Tb927.7.6620, and the genes encoding for the DNA
repair enzymes TbSNM1, TbMRE11, TbRAD51,
TbXPG, TbEXO1, TbCSB and TbMSH3) are expressed
at equivalent levels in RH1RC and control parasites.
Aziridinyl benzoquinones promote cell cycle arrest and
DNA damage in trypanosomes
Aziridinyl benzoquinones mediate their toxicity against
mammalian cells through formation of ICLs that promote
cell cycle arrest and DNA damage (Kim et al., 2004;
Dehn et al., 2005; Begleiter et al., 2007). To determine
if this is the case in T. brucei, parasites at various
stages in the cell cycle were identified in asynchronous
cultures by staining their nuclear (N) and mitochondrial
(known as the kinetoplast (K)) genomes with DAPI; a
non-dividing trypanosome cell usually contains one mito-
chondrion and hence one kinetoplast. The ratio of these
two DNA-containing structures represents an excellent
marker for the trypanosomal cell cycle, with T. brucei in
the G1/S phase having a 1N1K arrangement, those in
G2/M phase possessing a 1N2K ratio while cells dis-
playing a 2N2K profile are in the post-M stage (Wood-
ward and Gull, 1990; Siegel et al., 2008; Glover and
Horn, 2012). For untreated T. brucei and cells exposed
to phleomycin, most (approximately 80%) were in the
G1/S stage of the cell cycle with a smaller percentage
(12 to 20%) in G2/M (Fig. 5). In contrast, when trypano-
somes were treated with RH1 or mechlorethamine (a
well characterized ICL inducing agent), 58% and 45% of
the cells displayed a configuration typical of the G2/M
phase, respectively, with only 37% and 53% exhibiting a
1N1K DNA staining pattern, respectively. This indicates
that treatment of T. brucei with RH1 (or mechloreth-
amine) results in a G2/M cell cycle arrest phenotype,
potentially as a result of damaged DNA and is consist-
ent with observations made with mammalian cells
(Kim et al., 2004; Dehn et al., 2005).
In most cells, ICLs are repaired through the concerted
action of a number of complementary and overlapping
pathways with enzymes belonging to the SNM1/PSO2
family playing a specific role. In T. brucei, the enzyme
TbSNM1, a member of the SNM1/PSO2 nuclease fam-
ily, has been shown to play a specific and key role in
repairing such damage (Sullivan et al., 2015). To evalu-
ate whether deletion of both copies of Tbsnm1 from the
T. brucei genome altered the cells sensitivity to ABQs,
the null mutant trypanosomes were grown in the pres-
ence of selected trypanocidal quinones and the EC50
values for each compound determined (Table 4; Fig. 6).
For all the ABQ prodrugs tested, cells lacking the nucle-
ase were up to 6.6-fold more susceptible to these
Table 3. Susceptibility of RH1 resistant T. brucei to trypanocidal
agents.
EC50 values (nM)
Compound Wild type RH1RC1 ratio
Aziridines
Triethylenemelamine 24006 86 2774664 1.1
ThioTEPA 394236 796 5629861960 1.4
RH1a 256 6 8362* 3.3
ABQ22 1976 31 232627 1.2
CB1954a 21616 125 130866972* 6.5
Nitrogen mustards
Mechlorethamine 320636 1021 2720361288 0.8
Melphalan 87406 200 104306230 1.2
LH17a 54386 444 1799861106* 3.6
Nitrosoureas
Lomustine 166506 443 154636665 0.9
Semustine 150256 3457 1710063619 1.1
Other agents
DFMO 167636 2691 221776383 1.3
Nifurtimoxa 27006 100 70506311* 2.6
Megazola 1666 1 45464* 2.7
Data represent the growth-inhibitory effect as judged by their EC50
values of various agents on BSF T. brucei wild type and RH1RC1
cells. All values are means6 standard deviation from independent
experiments preformed in quadruplicate. The ratio represents the
fold difference in EC50 value between the RH1
RC1 and wild type
lines to a given compound.
a. Identifies TbNTR-activated prodrugs.
*Indicates significant differences in susceptibility (P < 0.001)
between wild type and RH1RC1 lines, as assessed by Student’s t
test (GraphPad Software).
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structures than control parasites. In contrast, assays
using ABQ23 and ABQ24, the two ABQs that do not
function as TbNTR- or TbCPR-activated prodrugs, and
the trypanocidal agents nifurtimox and DFMO, revealed
no significant difference in the EC50 exhibited by the
engineered and control lines.
To conclusively demonstrate that the above altered
susceptibility phenotype was solely due to lack of
TbSNM1 activity, the sensitivity of null mutant cells
expressing an ectopic copy of Tbsnm1 towards DZQ,
RH1 and ABQ22 was evaluated (Fig. 6). In all three
cases, the TbSNM1-complemented line generated dose
response curves and EC50 values distinct from those
observed when using TbSNM1 null mutant cells but sim-
ilar to those obtained using wild type parasites.
Linking prodrug activation with DNA damage
To establish whether there is a link between activation
of the trypanocidal ABQs and the TbSNM1-mediated
DNA repair pathway, the susceptibility of Tbsnm1 null-
mutants expressing ectopic copies of Tbntr or Tbcpr2
towards selected compounds was evaluated (Fig. 7).
When these lines were treated with RH1 or TZQ, an
Fig. 4. Evaluating the mechanism underlying RH1 resistance in T. brucei.
A. Schematic of T. brucei chromosome 7 that contains Tbntr. This gene is part of a 200 kbp polycistronic region (see Expanded view) that
encodes for 60 open reading frames (ORF) (light grey arrowed box) and is approx. 75 kbp downstream from a ‘strandswitch’ region, areas
on the trypanosomal chromosome that are postulated to be regions where polycistronic transcription is initiated (Imboden et al., 1987; Muhich
and Boothroyd, 1988). The position of selected ORFs from the Tbntr-containing polycistronic transcriptional unit plus the telomeric repeats
(black arrow repeats) are shown. Other selected polycistrons on chromosome 7 are also highlighted (dark grey arrowed boxes).
B and C. The mRNA levels (panel B) and gene copy number (panel C) of selected ORFs located on chromosome 7 from wild type (grey bar)
and RH1RC1 (white bar) cells was evaluated by qPCR. This was compared against the expression level/gene copy number of a standardized
control (Tbtert) and the average fold difference, as judged by 2–(DDCT) from reactions performed in triplicate6 standard deviation, plotted as
a measure of the relative expression level. The asterisk and double asterisk indicates significant differences in relative mRNA expression
levels (P <0.01 and <0.02, respectively) between the wild type and RH1RC1, as assessed by Student’s t test (GraphPad Software).
Fig. 5. RH1 promotes cell cycle arrest in T. brucei.
The effect of ICL inducing agents (mechlorethamine (HN2) or RH1) on
the trypanosome cell cycle was analysed by determining the relative
number of nuclear (N) andmitochondrial (K) genomes structures within a
single parasite. T. brucei in the G1/S phase have a 1N1K arrangement
(black bar), those in G2/M phase possess a 1N2K ratio (grey bar) while
cells displaying a 2N2K profile are in the post-M stage (hatched bar)
(Woodward and Gull, 1990; Siegel et al., 2008; Glover and Horn, 2012).
The number of cells (n) analysed for each treatment (untreated,
phleomycin treated, mechlorethamine (HN2) or RH1) is given.
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increased susceptibility was observed relative to wild
type controls (Fig. 7A); Tbsnm1 null-mutants and T. bru-
cei over expressing Tbntr were threefold and fivefold
more susceptible to RH1, respectively, and 2.7- and 3.4-
fold more susceptible to TZQ than wild type T. brucei.
For Tbsnm1 null parasites expressing an ectopic copy
of Tbntr, this increase in potency was magnified further,
with these cells showing a 15-fold increase in suscepti-
bility to both compounds as compared against wild type.
Extending these studies to investigate the susceptibility
of Tbsnm1 null-mutant parasites engineered to express
an ectopic copy of Tbcpr2 towards ABQ22 yielded simi-
lar results (Fig. 7B). When Tbsnm1 null mutants or wild
type cells engineered to express an ectopic copy of
Tbcpr2 were treated with ABQ22 a sevenfold increase
in susceptibility was observed by both lines compared
against controls. The growth inhibitory effect of this
compound was further enhanced in trypanosomes that
lack TbSNM1 activity while expressing elevated levels of
TbCPR2 (Fig. 7B), with these cells being 12.5-fold more
sensitive to ABQ22 than wild type. The above altera-
tions in susceptibilities were specific to the ABQs as all
lines tested exhibited equivalent sensitivities to the non-
DNA damaging trypanocidal agent DFMO.
Discussion
ICLs represent a highly toxic form of DNA damage that
blocks processes dependent on DNA strand separation,
such as replication and transcription. As rapidly dividing
cells are particularly susceptible to this type of lesion,
agents that are able to promote ICLs are of interest in
the treatment of cancer and infectious diseases (Chen
and Hu, 2009; Deans and West, 2011; Wilkinson et al.,
2011). Here, we report that several ABQs, ICL inducing
chemicals originally developed as anti-cancer agents,
can also function as highly potent anti-trypanosomatid
prodrugs with different structures able to undergo activa-
tion via different pathways. In these cases, activation
promotes a type of DNA damage that is repaired by a
pathway where SNM1, a nuclease that only functions in
ICL repair, plays a key role.
Invariably, aziridine-containing compounds function as
prodrugs with activation requiring protonation of the azir-
idinyl nitrogen. The ease with which this reaction can
occur is governed by the compound’s chemical compo-
sition and how this influences the pKa of the aziridine.
For certain structures (e.g., triethylenemelamine, thio-
TEPA and ‘simple’ ABQs including ABQ11) protonation
can readily take place in aqueous solution due to the
relatively high pKa of the aziridine within such back-
bones (Akhtar et al., 1975). However, for other agents,
the pKa of the heterocycle is comparatively low,
Fig. 6. Susceptibility of T. brucei lines expressing altered levels of TbSNM1 to selected azirindinyl benzoquinones. Growth inhibitory effects,
as judged by EC50 values, of RH1, TZQ and ABQ22 (all in nM) in the T. brucei wild type, Tbsnm1 null mutant (DTbsnm1) and Tbsnm1 null
mutants expressing an ectopic copy of Tbsnm1 (DTbsnm1 Tbsnm111) lines (Sullivan et al., 2015). DFMO (in mM) was used as a non-DNA
damaging agent control. Data are mean values6 standard deviations from experiments performed in quadruplicate. The asterisk indicates
significant differences in susceptibility (P <0.001) between wild type and DTbsnm1 or between DTbsnm1 and DTbsnm1 Tbsnm111 cells to
RH1, as assessed by Student’s t test (GraphPad Software).
Table 4. Susceptibility of T. brucei Tbsnm1 null mutants to ABQ
compounds.
EC50 (nM)
Compound Control DTbsnm1 Ratio
Nifurtimox 2850620 22506090 0.79
DFMO 275006108 271006850 0.99
DZQ 157623 4362* 0.27
RH1 1961 561* 0.26
TZQ 253633 4661* 0.18
ABQ22 138625 2165* 0.15
ABQ23 2300660 24106160 1.01
ABQ24 14706120 11306100 0.77
Data represent the EC50 values of selected ABQ compounds
towards wild type T. brucei (control) and T. brucei Tbsnm1 null
mutants (DTbsnm1). All values are means6 standard deviation of
four independent experiments. The ration of EC50 values between
the two parasite lines are given. *Indicates significant differences in
susceptibility (P < 0.01) between the wild type and DTbsnm1 lines,
as assessed by Student’s t test (GraphPad Software).
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therefore preventing the above activation event. To cir-
cumnavigate this issue, the aziridine motif can be incor-
porated into a chemical backbone that also contains a
bioreductive moiety, such as a quinone or nitroaromatic.
Here, enzymatic reduction of carbonyl oxygen or nitro
groups triggers a redistribution of electrons around the
associated cyclical structure that can raise the pKa of
the aziridinyl ring, and thus facilitating nitrogen protona-
tion (Fig. 8A) (Hargreaves et al., 2000).
Using a combination of a whole genome loss-of-
function screen, selection of resistant lines and/or
functional genomic approaches, we have shown that
T. brucei expresses at least two ABQ bioreductive sys-
tems. For the eight compounds evaluated as potential
prodrugs, half (DZQ, MeDZQ, RH1 and TZQ) were
shown to be NTR activated, one (ABQ22) was shown to
be dependent on a CPR activity, while the remainder
(ABQ23, 24 and 30) were not reduced by any of the
systems tested. For those that appeared not to function
as prodrugs, this may be due to their structures, as
these compounds contain methyl substituted aziridines
(Fig. 8B). These alkyl groups may block protonation and
thus activation of the aziridinyl nitrogen by lowering this
motif’s pKa and/or hinder access of oxidoreductases to
the carbonyl groups (Lusthof et al., 1989; Phillips et al.,
1999). These possibilities may also account for why
other compounds that contain methyl/dimethyl aziridine
substitutions (e.g., ABQs 25–30 and 31–34) consistently
displayed no or a lower activity against T. brucei than
their non-substituted counterparts, mirroring observa-
tions made in high throughput oncological screens (Kim
et al., 2016).
For those compounds that do function as trypanocidal
prodrugs, the nature of the side chains found at the 3,6
positions on the benzoquinone ring appears to influence
which activation mechanism predominates (Fig. 8B). For
structures possessing small substituents at one or both
sites, reduction occurs via a type I NTR activity with this
mechanism unaffected by the presence of equivalent
(e.g., hydrogen for DZQ, methyl for MeDZQ) or diver-
gent (e.g., hydroxymethyl and methyl in RH1, aziridine
and hydrogen in TZQ) groupings at the 3,6 positions.
Such small side chains may aid type I NTR/compound
interaction or help the prodrug (or its activated products)
Fig. 7. Linking aziridinyl benzoquinone prodrug activation to DNA damage.
A. Growth inhibitory effects, as judged by EC50 values, of RH1, TZQ, ABQ22 (all in nM) and DFMO (in mM) in the T. brucei wild type, T. brucei
expressing an ectopic copy of Tbntr (Tbntr11), Tbsnm1 null mutant (DTbsnm1) and Tbsnm1 null mutants expressing elevated levels of Tbntr
(DTbsnm1 Tbntr11) lines. The asterisk and double asterisk indicates significant differences in susceptibility (P <0.001 and <0.03,
respectively) between the DTbsnm1 Tbntr11 line relative to the Tbntr11 or DTbsnm1 parasites to RH1 and TZQ, as assessed by Student’s t
test (GraphPad Software).
B. Growth inhibitory effects, as judged by EC50 values, of RH1, TZQ and ABQ22 (all in nM) in the T. brucei wild type, T. brucei expressing an
ectopic copy of Tbcpr2 (Tbcpr211), Tbsnm1 null mutant (DTbsnm1) and Tbsnm1 null mutants expressing elevated levels of Tbcpr2 (DTbsnm1
Tbcpr211) lines: the latter lines was validated as previous described (Hall et al., 2011; Sullivan et al., 2015). DMFO (in mM) was used as a
non-DNA damaging agent control. The asterisk and double asterisk indicates significant differences in susceptibility (P 5 0.01 and P< 0.003,
respectively) between the DTbsnm1 Tbcpr211 line relative to the Tbcpr211 or DTbsnm1 parasites to ABQ22, as assessed by
Student’s t test (GraphPad Software).
Data in panels A and B are mean values6 standard deviations from experiments performed in quadruplicate.
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gain access to the site(s) of action. In contrast, the pres-
ence of bulkier groups (e.g., aziridines for ABQ22) at
both sites results in CPR activation. Why this mecha-
nism operates to reduce this particular compound is
open to speculation but it may reflect a steric hindrance
effect such that the four aziridine groups found in
ABQ22 preclude TbNTR from interacting with and
reducing its quinone carbonyl groups while facilitating
associations with TbCPR isoforms. Alternatively, this dif-
ference could be due to subcellular localisation such
that ABQ22 may be readily transported into the T. brucei
endoplasmic reticulum, the organelle where the TbCPRs
are believed to reside, but unable to gain access to the
parasite’s mitochondrion, the site where TbNTR is found
(Wilkinson et al., 2008).
Following protonation of the aziridinyl nitrogen, the
resultant electrophilic intermediate undergoes nucleo-
philic attack leading to opening of the heterocyclic ring,
formation of an aliphatic amine then alkylation of the tar-
get (Fig. 8A) (Hargreaves et al., 2000). If the targeting
compound contains multiple aziridinyl groups, as is the
case for the ABQs tested here, and the nucleophile is
DNA, then two nucleobases within the nucleic acid dou-
ble helix become covalently crosslinked. In many eukar-
yotes the SNM1 (also known as PSO2) nuclease plays
a key role in resolving such DNA damage, with cells
lacking this activity being specifically and highly
susceptible to ICL inducing agents (Cattell et al., 2010).
By phenotypically screening a selected set of trypanoci-
dal ABQs against a T. brucei snm1 null mutant line, we
demonstrated that trypanosomes lacking this DNA
repair enzyme were more susceptible to NTR and CPR
activated prodrugs relative to wild type. Moreover, in
parasites where TbSNM1 was absent but the activation
mechanism (either TbNTR or TbCPR) is elevated, this
susceptibility phenotype was exacerbated, providing a
direct link between the two oxidoreductase activities and
DNA damage. Extending these assays to investigate the
trypanocidal action of ABQs that do not undergo NTR or
CPR activation, revealed that these do not promote a
form of DNA damage that can be repaired through an
SNM1-dependent pathway. It is plausible that these
agents may still function as monofunctional or bifunc-
tional DNA alkylating agents, leading to formation of a
single site adduct or intrastrand crosslink or could act as
modifiers of other biological molecules via their aziridinyl
or quinone ring structures.
The continuous in vitro culturing of bloodstream form
T. brucei in the presence of RH1 generated a parasite
line that displayed cross-resistance to a range of NTR-
activated prodrugs. Analysis of clones revealed that
these cells had reduced Tbntr expression. Additionally,
lower mRNA levels were also noted for other open read-
ing frames across the 200 kb Tbntr-containing
Fig. 8. Proposed mechanism of action and trypanocidal structure activity relationships of ICL-forming ABQs.
A. Quinones can be reduced to hydroquinones by two distinct pathways. In one pathway, enzymes such as cytochrome P450 reductase
(CPR) mediate the 1e– reduction of the quinone to a semiquinone radical. This then undergoes further reduction to the hydroquinone. In the
presence of O2, the semiquinone can undergo futile cycling to form O
:2
2 and the parental quinone. In the other system, reduction of the
quinone to the hydroquinone occurs directly via a 2e- reduction event as typified by a type I nitroreductase (NTR) activity. Formation of the
hydroquinone then facilitates protonation of the nitrogen atoms in the aziridine rings with these electrophilic intermediates undergoing
nucleophilic attack (e.g., by DNA), promoting opening of the aziridinyls, formation of aliphatic amine intermediates and alkylation of the target.
As ABQs contain two (or more) aziridinyls they can covalently bind the two complementary DNA strands together resulting in an interstrand
crosslink.
B. ABQs (e.g., DZQ, MeDZQ, RH1 and TZQ) possessing small (e.g., hydrogen, methyl, hydroxymethyl) substituent groups (small solid
spheres) at the 3,6 positions on a benzoquinone core are more likely to be activated in T. brucei by the type I nitroreductase (NTR) but not by
cytochrome P450 reductase (CPR) (i). ABQs that contain methyl substituted (small solid spheres) aziridines (e.g., ABQ23, 24 and 30) are not
activated in T. brucei by NTR or CPR (ii). ABQ22, a compound that contains aziridinyl rings at the 3,6 positions on the benzoquinone core, is
readily activated within the trypanosome by CPR but not by NTR (iii). ABQs (e.g., ABQ9–19) having bulky substituent groups (large solid
spheres) at the 3,6 positions on the benzoquinone ring generally display no significant trypanocidal activity (iv).
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polycistron; however, this effect did not extend to the
surrounding transcriptional units. In contrast to trypano-
somes selected for resistance towards other NTR acti-
vated prodrugs such as nifurtimox or fexinidazole
(Wilkinson et al., 2008; Wyllie et al., 2016), the copy
number of all tested open reading frames in the Tbntr-
containing transcriptional unit were equivalent to wild
type, indicating that the observed reduction in gene
expression was not due to a large (>10 kb) DNA dele-
tion event; the ‘strandswitch’ region, areas on the trypa-
nosomal chromosome postulated to be regions where
polycistronic transcription is initiated (Imboden et al.,
1987; Muhich and Boothroyd, 1988), between the Tbntr-
containing and adjacent transcriptional units is 6 kb.
Although the exact molecular basis that leads to RH1
resistance has yet to be deciphered, it is plausible that
the transcription initiation site of one of the two Tbntr-
containing polycistrons (T. brucei has a diploid nuclear
genome) may have been compromised resulting in the
reduction in mRNA levels.
We have demonstrated that ABQs display significant
growth inhibitory activities against T. brucei, T. cruzi and
L. major, with two compounds (RH1 and TZQ) exhibiting
high potency (EC50 values< 100 nM) against all three
pathogens. However, this is accompanied by toxicity
against macrophage (-like) mammalian cells, a trait previ-
ously noted in primary mouse splenocytes (Miliukiene
et al., 2014). This unwanted activity may be because
such immune cells have the ability to constitutively
express or to upregulate quinone oxidoreductases includ-
ing NQO1 and NQO1-independent activities that promote
oxidative stress and/or DNA damage (Tudor et al., 2005;
Potts-Kant et al., 2012; Miliukiene et al., 2014). Although
these cytotoxicity issues may preclude the use of these
ABQs as therapies for the treatment of systemic infec-
tions, understanding how they mediate their trypanocidal
activities can inform drug development. By exploiting the
chemical features that facilitate NTR or CPR specific acti-
vation such as those reported here, novel trypanocidal
prodrugs could be generated. Following their activation,
these compounds could be designed to release cytotoxic
metabolites that affect a range of biological processes
potentially targeting different biochemical pathways. Such
agents would be best used in a polytherapy, as is the
case with the anti-HAT nifurtimox-eflornithine combination
therapy, in order to minimize potential resistance.
Experimental procedures
Compounds
The compounds used in this study were obtained from the
following sources: The aziridinyl benzoquinones (DZQ,
MeDZQ, AZQ, TZQ and ABQ3–4, 6–19, 22–34) (Table 5)
Table 5. Structure of aziridinyl 1,4-benzoquinones used in this study.
Compound Structure Compound Structure
ABQ1 (DZQ) R15R25X5Y5H ABQ18 R15R25NHCO(CH2)5CH3; X5Y5H
ABQ2 (MeDZQ) R15R25CH3; X5Y5H ABQ19 R15R25NHCOPhenyl; X5Y5H
ABQ3 R15R25Br; X5Y5H ABQ20 (AZQ) R15R25NHC(O)OCH2CH3; X5Y5H
ABQ4 R15R25F; X5Y5H ABQ21 (TZQ) R15azirindyl; R25X5Y5H
ABQ5 (RH1) R15CH2OH; R25CH3; X5Y5H ABQ22 R15R25azirindyl; X5Y5H
ABQ6 R15R25OCH3; X5Y5H ABQ23 R15R25X5H;Y5CH3 (r orientation)
ABQ7 R15R25OCH2CH3; X5Y5H ABQ24 R15R25X5H;Y5CH3 (s orientation)
ABQ8 R15R25O(CH2)2CH3; X5Y5H ABQ25 R15R25Br; X5H; Y5CH3
ABQ9 R15R25NH2; X5Y5H ABQ26 R15R25Br; X5Y5CH3
ABQ10 R15R25NHCH3; X5Y5H ABQ27 R15R25Cl; X5H;Y5CH3
ABQ11 R15R25NHCH2CH3; X5Y5H ABQ28 R15R25Cl; X5Y5CH3
ABQ12 R15R25NH(CH2)6CH3; X5Y5H ABQ29 R15R25F; X5H;Y5CH3
ABQ13 R15R25NH(CH3)CH3; X5Y5H ABQ30 R15R25F; X5Y5CH3
ABQ14 R15morpholinyl; R25F; X5Y5H ABQ31 R15R25NHCOCH3; X5H; Y5CH3
ABQ15 R15R25NHCOCH3; X5Y5H ABQ32 R15R25NHCOCH3; X5Y5CH3
ABQ16 R15R25NHCOCH2CH3; X5Y5H ABQ33 R15R25NHCOCH2CH3; X5H;Y5CH3
ABQ17 R15R25NHCO(CH2)2CH3; X5Y5H ABQ34 R15R25NHCOOCH2CH3; X5Y5CH3
All compounds tested satisfy Lipinski’s Rule of 5 (http://pubchem.ncbi.nlm.nih.gov/) although all are predicted to have toxicity risks (http://www.
organic-chemistry.org/prog/peo).
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were supplied by the Drug Synthesis and Chemistry
Branch, Developmental Therapeutics Program, Division of
Cancer Treatment and Diagnosis, National Cancer Institute,
United States, while RH1 was donated by Prof Frank
Guziec Jr (Southwestern University, TX). The chemical,
physical and potential toxicological properties of each
compound can be accessed via the PubChem database
(http://pubchem.ncbi.nlm.nih.gov/) or OSIRIS Property
Explorer software (http://www.organic-chemistry.org/prog/).
Nifurtimox was obtained from Prof Simon Croft (London
School of Hygiene and Tropical Medicine, UK), DFMO from
Prof Mike Barrett (University of Glasgow, UK), mechloreth-
amine HCl from Stratech Scientific, while puromycin, blasti-
cidin, phleomycin, hygromycin b and tetracycline were
purchased from Melford Laboratories.
Cell culturing
Bloodstream form T. brucei brucei (MITat 427 strain; clone
221a) cells were cultured in HMI-9 media (Life Technolo-
gies) supplemented with 36 mM sodium bicarbonate,
0.014% (v/v) b-mercaptoethanol and 10% (v/v) heat-
inactivated foetal calf serum (GE Healthcare) as described
(Hirumi and Hirumi, 1989). A cell line (2T1) engineered to
constitutively express the tetracycline repressor protein was
grown in the modified HMI-9 medium, supplemented with 1
lg ml21 phleomycin (Alsford et al., 2005). T. brucei Tbntr
heterozygote lines were cultured in the presence of 10
lg ml21 blasticidin while transformed 2T1 parasites over
expressing Tbntr, Tbcpr2 or Tbcpr3 were maintained in the
modified HIM-9 medium supplemented with 1 lg ml21
phleomycin, 2.5 lg ml21 hygromycin b and, where appropri-
ate, 1 lg ml21 tetracycline to induce protein expression
(Hall et al., 2011). T. brucei lines expressing altered levels
of the DNA repair enzyme TbSNM1 were grown in the
presence 1 lg ml21 phleomycin, 10 lg ml21 blasticidin and/
or 2 lg ml21 puromycin, as appropriate (Sullivan et al.,
2015).
The epimastigote form of T. cruzi was cultured in RPMI-
1640 medium (Lonza) supplemented with 5 g l21 trypticase,
5 g l21 HEPES pH 8.0, 20 mg l21 haemin, 0.34 g l21
sodium glutamate, 0.22 g l21 sodium pyruvate, 2500 U l21
penicillin, 0.25 g l21 streptomycin (all Sigma-Aldrich) and
10% (v/v) heat-inactivated foetal calf serum (GE Health-
care) at 258C (Kendall et al., 1990).
The promastigote form of L. major MHOM/IL/80/Friedlin
was cultured at 258C in modified M199 medium (Invitrogen)
supplemented with 4 mM sodium bicarbonate, 40 mM
HEPES pH 7.4, 0.1 mM adenine, 0.005% (w/v) haemin (all
Sigma-Aldrich), 25000 U l21 penicillin, 25 mg l21 streptomy-
cin (GE Healthcare) and 10% (v/v) heat-inactivated foetal
bovine serum (GE Healthcare) (Kapler et al., 1990).
The human acute monocytic leukemia (THP-1) cell line
was grown at 378C under a 5% (v/v) CO2 atmosphere in
RPMI-1640 medium (Lonza) supplemented with 2 mM pyru-
vate, 2 mM sodium glutamate, 2.5 U ml21 penicillin and 2.5
lg ml21 streptomycin, 20 mM HEPES pH 7.4 and 10% (v/
v) heat-inactivated foetal calf serum (GE Healthcare). Dif-
ferentiation of THP-1 toward macrophage-like cells was
carried out using 20 ng ml21 phorbol 12-myristate 13-ace-
tate (Sigma-Aldrich) (Rovera et al., 1979).
Selective screening of the T. brucei RNAi library
Selection of the T. brucei RNAi library was performed as
described (Glover et al., 2015). Parasites (5 3 106 cells)
were treated for 24 hours with 1 lg ml21 tetracycline to
induce RNAi prior to addition of 30 nM RH1. Periodically,
the cell density of the culture was determined and when
appropriate, diluted in growth medium containing fresh RH1
(30 nM) and tetracycline (1 mg ml21). Once an outgrowth
population had been selected, genomic DNA was prepared
for RNAi target identification (Alsford et al., 2012).
Selection of laboratory generated RH1-resistant T.
brucei
Wild type bloodstream form T. brucei seeded at 1 3 104
cells ml21, were cultured in the presence of sub-lethal con-
centration of RH1 (5 nM). Over a 100 day period, the ABQ
concentration in the culture media was increased in a step-
wise manner reaching a final concentration of 40 nM. The
resulting line (designated as RH1R) was cloned by limiting
dilution in the presence of RH1 and the phenotype of two
clones (RH1RC1 and RH1RC2) analysed.
Parasite growth inhibition assays
All growth inhibition assays were carried out in a 96-well
plate format (ThermoScientific). Bloodstream form T. brucei,
L. major promastigotes and T. cruzi epimastigotes parasites
in the logarithmic phase of growth were seeded at 1 3 104,
5 3 105 and 5 3 105 cells ml21 respectively in 200 ll
growth medium containing different concentrations of the
compound under study. After incubation at 378C for 3 days
(T. brucei), 258C for 6 days (L. major) or 258C for 14 days
(T. cruzi), resazurin (Sigma Aldrich) was added to each well
at a final concentration of 12.5 mg ml21 (or 2.5 mg per well).
The plates were further incubated at 378C for 8 hours (T.
brucei), 258C for 24 hours (L. major) or 258C for 24–48
hours (T. cruzi) before measuring the fluorescence of each
culture using a Gemini Fluorescent Plate reader (Molecular
Devices) set at kEX5 530 nm and kEM5 585 nm with a fil-
ter cut off at 550 nm. The change in fluorescence resulting
from the reduction of resazurin is proportional to the num-
ber of live cells. A compound’s EC50 value was established
using the non-linear regression tool on GraphPad Prism
(GraphPad Software) and the statistical significance of any
differences in parasite susceptibilities assessed using the
Student’s t test calculator (GraphPad Software).
Mammalian inhibition assays
Differentiated THP-1 cells seeded at 2.5 3 104 cells ml21
were incubated for 3 days at 378C in a 5% (v/v) CO2
atmosphere in 200 ll modified RMPI-1640 growth medium
containing various concentrations of the compound under
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study. Resazurin (2.5 mg per well) was added to each cul-
ture and the plates incubated for a further 8 hours before
determining the fluorescence of each sample.
Experiments involving animals were approved by the Ani-
mal Welfare and Ethics Review Board at LSHTM and con-
ducted under license in accordance with the Animals
(Scientific Procedures) Act 1986 (UK Home Office Project
Licence PPL70/6997). Peritoneal macrophages were iso-
lated from BALB/c mice by lavage 24 hours after intraperi-
toneal injection of 2% (w/v) soluble starch (Sigma).
Macrophages (40,000) in RPMI-1640 medium (Lonza) sup-
plemented with 10% (v/v) heat-inactivated foetal calf serum
(GE Healthcare) were adhered overnight at 378C in a 5%
(v/v) CO2 atmosphere onto a 16-well chamber slide. Cells
were then treated with various concentrations of the com-
pound under study and the cultures incubated at 378C up
to 5 days under a 5% (v/v) CO2 atmosphere. Untreated
controls were analysed in parallel on each slide. Macro-
phages were fixed in 100% (v/v) methanol, stained with
10% (w/v) Giemsa, visualized with Leica DMRA2 light
microscope using a 3100 oil immersion objective and
images captured using a Retiga EXi Fast 1394 digital cam-
era. The number of cells per field of view was determined
with a minimum of 10 fields examined for each drug treat-
ment. The average number of cells per field of view was
determined and expressed as a % relative to untreated
controls. All treatments were performed in quadruplicate.
Quantitative PCR (qPCR)
The copy number and mRNA levels of various genes were
analysed by qPCR. Genomic DNA or total RNA was pre-
pared from wild type or RH1-resistant T. brucei using the
DNeasy Blood and Tissue or RNeasy Extraction kits (Qia-
gen), respectively. cDNA was synthesized from total RNA
using the Superscript VILO cDNA synthesis kit (Invitrogen).
All qPCRs were performed in triplicate with the PerfeCTa
qPCR FastMix kit (Quanta Biosciences) on a CFX96 Touch
Real-Time PCR Detection System (BioRad). Fluorescence
data was collected using the CFX Manager Software (Bio-
Rad), the products analysed by a melt curve after the final
cycle and normalized against telomerase reverse transcrip-
tase (Tbtert; Tb11.01.10190) using the comparative CT
method (Schmittgen and Livak, 2008; Brenndorfer and
Boshart, 2010).
Cell cycle arrest assay
Wild type T. brucei (5 3 105 ml21) were cultured for 16
hours in the presence of mutagen (1 mg ml21 phelomycin;
35 mM mechlorethamine; 100 nM RH1). Cells were washed
in phosphate buffered saline (PBS), fixed in 2% (w/v) para-
formaldehyde in PBS and washed once more in PBS. Ali-
quots of the cell suspension (105 cells) were air-dried
onto microscope slides and the samples mounted in
Vectashield containing 4, 6-diamidino-2-phenylindole
(Vector Laboratories). Images were captured using Leica
DMRA2 epi-fluorescent microscope fitted with a digital cam-
era (Hamamatsu Photonics).
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